The University of Oxford’s possible COVID-19 vaccine could be rolled out by the end of the year but there is no certainty, the lead developer of the vaccine said on Tuesday.
The experimental vaccine, which has been licensed to AstraZeneca, produced an immune response in early-stage clinical trials, data showed on Monday, preserving hopes it could be in use by the end of 2020.
For more coronavirus news, visit our dedicated page.
“The end of the year target for getting vaccine roll-out, it’s a possibility but there’s absolutely no certainty about that because we need three things to happen,” Sarah Gilbert told BBC Radio.
She said it needed to be shown to work in late-stage trials, there needed to be large quantities manufactured, and regulators had to agree quickly to license it for emergency use before large numbers of people could be vaccinated.
Coronavirus: COVID-19 can live on face masks for days amid pandemic, scientist warns
England’s Chief Medical Officer Chris Whitty and his deputy Jonathan Van-Tam took differing views on the potential timeline.
“The chance of us getting a vaccine before Christmas that actually is highly effective are, in my view, very low,” Whitty told lawmakers.
Van-Tam, however, said he was “cautiously optimistic that we will have some vaccine this side of Christmas.”
The Oxford scientists had eyed a million doses of the potential vaccine to be produced by September.
For all the latest headlines follow our Google News channel online or via the app
Although the deal with AstraZeneca has provided manufacturing capacity to do that, the lower prevalence of the novel coronavirus in Britain has complicated the process of proving its efficacy.
Late-stage trials crucial for providing data are under way in Brazil and South Africa and are due to start in the United States also.
There are no approved vaccines yet for COVID-19, but the World Health Organization has said AstraZeneca’s shot is one of the leading candidates.
‘Positive news’ soon on Oxford, AstraZeneca COVID-19 vaccine: ITV editorPositive news on initial trials of the University of Oxford's potential COVID-19 vaccine that has been licensed to AstraZeneca could be announced as ... Coronavirus
Oxford’s potential COVID-19 vaccine shows ‘right sort of immune response’: ScientistA leading scientist behind the University of Oxford's potential COVID-19 vaccine said on Wednesday the team has seen the right sort of immune response ... Coronavirus
Clinical trials with Oxford coronavirus vaccine start in BrazilHuman clinical trials in Brazil for a potential coronavirus vaccine developed by Oxford University started this weekend, sponsor Lemann Foundation ... Coronavirus
UAE’s G42, UK’s Oxford Nanopore to develop ‘population-scale’ coronavirus testingGroup 42 (G42), a UAE-based artificial intelligence and cloud computing company, and UK-based Oxford Nanopore have announced they will develop a high ... Coronavirus
Coronavirus: Oxford's vaccine trial has 50 percent chance of successThe University of Oxford's COVID-19 vaccine trial has only a 50 percent chance of success as the coronavirus seems to be fading rapidly in Britain, ... Coronavirus
UK drugmaker AstraZeneca gets $1 bln in US funding to make Oxford coronavirus vaccineAstraZeneca Plc received more than $1 billion in US funding to develop a Covid-19 vaccine from the University of Oxford and said it has supply ... Coronavirus
Coronavirus: Oxford virus vaccine found protective in small monkey studyA closely watched coronavirus vaccine being developed by scientists at Oxford University appears protective in a small study of six monkeys, promising ... Coronavirus
Half of the UK population could have coronavirus: Oxford studyHalf of the population of the United Kingdom could already be infected with the novel coronavirus, a recent study has posited, as experts now say the ... World News